Baicalin inhibits the TGF-&#x03B2;1/p-Smad3 pathway to suppress epithelial-mesenchymal transition-induced metastasis in breast cancer

Ding-Kuo Liu; Hui-Feng Dong; Rui-Fen Liu; Xi-Long Xiao

doi:10.18632/oncotarget.27677

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Baicalin inhibits the TGF-β1/p-Smad3 pathway to suppress epithelial-mesenchymal transition-induced metastasis in breast cancer

Ding-Kuo Liu, Hui-Feng Dong, Rui-Fen Liu and Xi-Long Xiao _

PDF | Full Text | How to cite

Oncotarget. 2020; 11:2863-2872. https://doi.org/10.18632/oncotarget.27677

Metrics: PDF 1397 views | Full Text 1901 views | ?

Abstract

Ding-Kuo Liu1, Hui-Feng Dong2, Rui-Fen Liu3^,4 and Xi-Long Xiao1

1 Department of Veterinary Medicine, China Agricultural University, Haidian District, Beijing, China

2 S&E Burgeoning Biotechnology (Tianjin) Co., Ltd, Wangwenzhuang Industrial Park, Xiqing District, Tianjin, China

3 Tianjin Key Laboratory of Microbial Preparation Enterprise for Feeding, Wangwenzhuang Industrial Park, Xiqing District, Tianjin, China

4 Tianjin Chinese Veterinary Medicine Technology Engineering Center, Huayuan Industrial Park, Tianjin, China

Correspondence to:

Xi-Long Xiao,

email:

[email protected]

Keywords: baicalin; TGF-β1; p-Smad3; epithelial-mesenchymal transition; breast cancer

Received: September 18, 2017 Accepted: February 26, 2018 Published: July 21, 2020

ABSTRACT

TGF-β1 is an epithelial-mesenchymal transition (EMT)-inducing factor that is critical in tumor progression. However, whether the effect of TGF-β1 on breast cancer is through the EMT pathway remains to be determined, and drug development based on this mechanism needs to be improved. Results of this study showed that TGF-β1 dysregulation significantly correlated with the expression levels of EMT-associated markers and transcriptional factors. Exogenous expression of TGF-β1 promoted breast cancer cell metastasis and EMT progression. In addition, direct binding of baicalin to TGF-β1 caused its inactivation, which subsequently blocked signal transduction and inhibited breast cancer cell metastasis. In vivo experiment results further invalidated the inhibitory effect of baicalin on TGF-β1-induced tumor metastasis. These results suggest that baicalin, an active ingredient used in traditional Chinese medicine, exhibits a potential therapeutic effect on breast cancer metastasis by regulating TGF-β1-dependent EMT progression.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27677

Publication Alerts

Research Papers:

Baicalin inhibits the TGF-β1/p-Smad3 pathway to suppress epithelial-mesenchymal transition-induced metastasis in breast cancer

Abstract